WuXi XDC signed an exclusive licensing and CRDMO agreement with AI‑driven biologics developer Earendil Labs giving Earendil access to the WuXiTecan‑2 payload‑linker technology to build next‑generation antibody‑drug conjugates. Financial terms include up to $885 million in upfront and milestone payments plus tiered royalties. Under the deal WuXi XDC will support manufacturing of linker and payload components using its end‑to‑end bioconjugation platform, while Earendil will apply the technology to its bispecific and multispecific ADC pipeline. Earendil said the license complements its AI‑driven discovery programs and could accelerate ADC builds against several oncology targets. The pact demonstrates converging industry strategies: AI‑first therapeutic design tied to specialized linker/payload chemistry and outsourced manufacturing to speed ADC translation. The size of the deal signals continued investor and industry appetite for ADC platform partnerships.